Drug interactions of clinical significance with selective serotonin reuptake inhibitors

Drug Safety : an International Journal of Medical Toxicology and Drug Experience
P B Mitchell

Abstract

The selective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors (SSRIs) have internationally become the accepted 'benchmark' class of antidepressants. It has become clear, however, that there are a number of clinically significant interactions between SSRIs and other medications. The most frequently described interactions are pharmacokinetic, which are far more prevalent than pharmacodynamic interactions. This article details those medications that may interact significantly with the SSRIs, and provides clinical guidelines for minimising the likelihood of such complications. The most common pharmacokinetic interactions are caused by an inhibitory effect of the SSRIs on the hepatic cytochrome P450 (CYP) metabolic system. The SSRIs differ in their potency in inhibiting a number of important CYP isoenzymes (CYP1A2, CYP2C9/10, CYP2C19, CYP2D6 and CYP3A3/4). The major outcome of concern in relation to pharmacodynamic interactions is the development of the 'serotonin syndrome'. While combination of the SSRIs with the irreversible monoamine oxidase inhibitors is the most recognised cause of this syndrome, concurrent administration with moclobemide, tryptophan or selegiline (deprenyl) may also lead to a similar outcome.

Citations

Feb 12, 2009·European Journal of Clinical Pharmacology·Ylva BöttigerBirgit Eiermann
Mar 20, 2010·Journal of Medical Toxicology : Official Journal of the American College of Medical Toxicology·Elizabeth L ThorpeJessica Boyer
Feb 27, 1999·Journal of Clinical Pharmacy and Therapeutics·E Tanaka
Mar 24, 2005·The New England Journal of Medicine·Edward W Boyer, Michael Shannon
Jul 11, 2012·Proceedings of the National Academy of Sciences of the United States of America·Parastoo HashemiR Mark Wightman
Oct 22, 2008·Nutrition & Metabolism·Zakia Bibi
Dec 4, 2004·Clinical Chemistry and Laboratory Medicine : CCLM·Philip B Mitchell
Aug 5, 2000·Clinical Pharmacokinetics·E L Michalets, C R Williams
Aug 23, 2002·Clinical Pharmacokinetics·Uwe ChristiansAlfonso Lampen
Apr 2, 2003·The British Journal of Psychiatry : the Journal of Mental Science·K L L MovigA C G Egberts
Sep 21, 2013·Neurocritical Care·Swetha PedavallyAlejandro A Rabinstein
Apr 12, 2000·British Journal of Clinical Pharmacology·P B Mitchell
Nov 28, 2006·Expert Opinion on Drug Metabolism & Toxicology·Emilio SternieriAnna Ferrari
Aug 23, 2008·Journal of Oral and Maxillofacial Surgery : Official Journal of the American Association of Oral and Maxillofacial Surgeons·Brian Szakaly, Robert Strauss
Aug 30, 2008·British Journal of Clinical Pharmacology·Clare RinglandSallie-Anne Pearson
Mar 27, 2007·Journal of Clinical Pharmacy and Therapeutics·S AilawadhiM R Baer
Nov 24, 2012·Journal of Diabetes·Usha SambamoorthiGeorge Rust
Jan 13, 2001·Dermatologic Clinics·H Tennyson, N Levine
Jan 25, 2008·The International Journal of Neuropsychopharmacology·Michael PaulzenGerhard Gründer
May 23, 2000·Drug Metabolism and Drug Interactions·M W Jann, L J Cohen
Apr 14, 1999·The Annals of Pharmacotherapy·V PalopI Martínez-Mir
Mar 3, 2007·Journal of Psychopharmacology·Simon J C DaviesJohn Potokar
Jun 14, 2002·American Journal of Veterinary Research·Leah A CohnBalazs Szladovits
Nov 24, 2004·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Raymond G SchliengerChristoph R Meier
May 12, 2019·International Journal of Molecular Sciences·James FrancescangeliAnthony Bonavia
Feb 22, 2003·CNS Drug Reviews·Udo Bonnet
Aug 9, 2003·Expert Opinion on Drug Safety·Kelly C LeeBrian K Alldredge
Nov 27, 2019·Cranio : the Journal of Craniomandibular Practice·David Dean
Feb 13, 2001·British Journal of Clinical Pharmacology·P McManusJ Dudley
Sep 17, 2019·International Journal of Tryptophan Research : IJTR·William J ScottonNicholas M Barnes
Feb 7, 2001·Arquivos de neuro-psiquiatria·L O Cavallazzi, A K Grezesiuk
Dec 15, 2020·The Journal of Emergency Medicine·Brian P MurrayZiad Kazzi

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.